Evidence map›Paper›PMID 42576811›Full record

ArticleCirculation2026

ABHD11-Mediated mtDNA Transcription Restored Mitochondrial Function to Attenuate Cardiomyocyte Ferroptosis After Myocardial Infarction.

Yu Liu, Yijin Chen, Hao Zheng, Yingxuan Li, Chuling Li, Wenlong Xu, Wei Chen, Zhiwen Xiao, Guojun Chen, Senlin Huang and 7 more

Abstract read
In one paragraph

Article in Circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yu Liu *Department of Cardiology and State Key Laboratory of Multi-organ Injury Prevention and Treatment, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y. Liu, Yijin Chen, H.Z., Y. Li, W.X., W.C., G.C., S.H., X.L., Y. Liao, J.B., Yanmei Chen).
Yijin Chen *Department of Cardiology and State Key Laboratory of Multi-organ Injury Prevention and Treatment, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y. Liu, Yijin Chen, H.Z., Y. Li, W.X., W.C., G.C., S.H., X.L., Y. Liao, J.B., Yanmei Chen).
Hao ZhengDepartment of Cardiology and State Key Laboratory of Multi-organ Injury Prevention and Treatment, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y. Liu, Yijin Chen, H.Z., Y. Li, W.X., W.C., G.C., S.H., X.L., Y. Liao, J.B., Yanmei Chen).
Yingxuan LiDepartment of Cardiology and State Key Laboratory of Multi-organ Injury Prevention and Treatment, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y. Liu, Yijin Chen, H.Z., Y. Li, W.X., W.C., G.C., S.H., X.L., Y. Liao, J.B., Yanmei Chen).ORCID 0009-0004-2041-7097
Chuling LiCardiovascular Center, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China (C.L., Z.X., Y. Liao, J.B.).
Wenlong XuDepartment of Cardiology and State Key Laboratory of Multi-organ Injury Prevention and Treatment, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y. Liu, Yijin Chen, H.Z., Y. Li, W.X., W.C., G.C., S.H., X.L., Y. Liao, J.B., Yanmei Chen).ORCID 0009-0008-9814-4198
Wei ChenDepartment of Cardiology and State Key Laboratory of Multi-organ Injury Prevention and Treatment, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y. Liu, Yijin Chen, H.Z., Y. Li, W.X., W.C., G.C., S.H., X.L., Y. Liao, J.B., Yanmei Chen).
Zhiwen XiaoCardiovascular Center, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China (C.L., Z.X., Y. Liao, J.B.).ORCID 0000-0002-7271-3961
Guojun ChenDepartment of Cardiology and State Key Laboratory of Multi-organ Injury Prevention and Treatment, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y. Liu, Yijin Chen, H.Z., Y. Li, W.X., W.C., G.C., S.H., X.L., Y. Liao, J.B., Yanmei Chen).
Senlin HuangDepartment of Cardiology and State Key Laboratory of Multi-organ Injury Prevention and Treatment, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y. Liu, Yijin Chen, H.Z., Y. Li, W.X., W.C., G.C., S.H., X.L., Y. Liao, J.B., Yanmei Chen).ORCID 0000-0002-1649-3044
Xinzhong LiDepartment of Cardiology and State Key Laboratory of Multi-organ Injury Prevention and Treatment, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y. Liu, Yijin Chen, H.Z., Y. Li, W.X., W.C., G.C., S.H., X.L., Y. Liao, J.B., Yanmei Chen).ORCID 0000-0001-7447-9315
Jia-Guo ZhouGuangdong Province Key Laboratory of Brain Function and Disease (J.-G.Z.), Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0003-1218-7565
Ying WuDepartment of Biostatistics, Southern Medical University, Guangzhou, China (Y.W.).
Wangjun LiaoDepartment of Oncology, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China (W.L.).
Yulin LiaoDepartment of Cardiology and State Key Laboratory of Multi-organ Injury Prevention and Treatment, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y. Liu, Yijin Chen, H.Z., Y. Li, W.X., W.C., G.C., S.H., X.L., Y. Liao, J.B., Yanmei Chen).
Jianping BinDepartment of Cardiology and State Key Laboratory of Multi-organ Injury Prevention and Treatment, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y. Liu, Yijin Chen, H.Z., Y. Li, W.X., W.C., G.C., S.H., X.L., Y. Liao, J.B., Yanmei Chen).ORCID 0000-0003-4799-1502
Yanmei ChenDepartment of Cardiology and State Key Laboratory of Multi-organ Injury Prevention and Treatment, Nanfang Hospital, Southern Medical University, Guangzhou, China (Y. Liu, Yijin Chen, H.Z., Y. Li, W.X., W.C., G.C., S.H., X.L., Y. Liao, J.B., Yanmei Chen).ORCID 0009-0005-0576-483X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiomyocytes exhibit marked susceptibility to ferroptosis after myocardial infarction (MI), rendering ferroptosis inhibition a promising therapeutic strategy to mitigate ischemic myocardial injury. Although mitochondrial dysfunction is recognized as a core driver of ferroptosis, the potential role of mitochondrial DNA transcription in regulating cardiomyocyte ferroptosis remains unexplored.

methodsTo clarify the temporal role of the various modes of cell death in MI progression, we performed time-course echocardiography in MI models treated with various cell death inhibitors. To characterize the crucial process and molecular regulator in cardiomyocyte ferroptosis, we integrated RNA sequencing and single-nucleus RNA sequencing data from murine post-MI hearts and performed functional rescue experiments using mitochondrial protective agents. To determine the role of ABHD11 (αβ-hydrolase domain-containing protein 11) in cardiomyocyte ferroptosis and cardiac repair after MI, we used loss- and gain-of-function approaches. To elucidate the underlying mechanisms, we conducted transcriptomics, nontargeted lipidomics, site-specific mutagenesis, molecular docking, coimmunoprecipitation, native gel electrophoresis, proximity ligation assay, methylation-specific polymerase chain reaction, and chromatin immunoprecipitation assay.

resultsWe found that cardiac ferroptosis peaked at day 7 after MI and was enriched in peri-infarct cardiomyocytes. Mitochondrial dysfunction was a key driver of cardiomyocyte ferroptosis after MI, and the lipid enzyme ABHD11 was identified as a potential regulator of both processes. ABHD11 expression was consistently reduced in mouse and human MI hearts, and its transcription was repressed by DNMT1 (DNA methyltransferase 1)-mediated promoter hypermethylation. Functionally, cardiac-specific overexpression of ABHD11 markedly alleviated cardiomyocyte ferroptosis and improved cardiac function after MI. Conversely, loss of ABHD11 in adult mice exacerbated pathological cardiac remodeling and heart failure. Mechanistically, independent of its canonical enzymatic activities, ABHD11 acted as a mitochondrial DNA transcription coactivator by enhancing the TEFM (mitochondrial transcription elongation factor)-POLRMT (mitochondrial RNA polymerase) interaction. This promoted mitochondrial DNA transcription, restored mitochondrial function, and reduced reactive oxygen species/PUFA-PLs (polyunsaturated fatty acid-containing glycerophospholipids)-driven lipid peroxidation and 4-hydroxynonenal generation. The reduction in 4-hydroxynonenal stabilized YY1 (Yin Yang 1), which subsequently regulated key ferroptosis-driving genes governing iron deposition, reactive oxygen species production, and polyunsaturated fatty acid lipids accumulation, further inhibiting lipid peroxidation and ferroptosis, and ultimately promoting cardiac recovery after MI.

conclusionsThis study revealed that ABHD11-mediated mitochondrial DNA transcription attenuated cardiomyocyte ferroptosis after MI by orchestrating a mitochondrial-nuclear crosstalk, offering a novel therapeutic strategy for ischemic myocardial injury.

Indexed as

DNA, MitochondrialFerroptosisMitochondria, HeartMyocardial InfarctionMyocytes, CardiacTranscription, GeneticAnimalsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLMice, KnockoutDNA, Mitochondrialferroptosismitochondriamyocardial infarctiontranscription

Identifiers

PMID42576811
PMCPMC13592836

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.